SCHEMBL219463

SCHEMBL219463

O=[N+]([O-])/C=C/c1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 13/20 1.00
EGFR P00533 2/20 0.64
ALDH1A1 P00352 3/20 0.58
LMNA P02545 3/20 0.58
MAPT P10636 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
TLR4 O00206 1/20 0.55
TLR2 O60603 1/20 0.55
ABL1 P00519 1/20 0.53
ABL2 P42684 1/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
VCP P55072 1/20 0.53
HSP90AA1 P07900 2/20 0.52
S1PR4 O95977 1/20 0.51
HPGD P15428 1/20 0.51
S1PR1 P21453 1/20 0.51
MAPK1 P28482 1/20 0.51
CCR6 P51684 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28528161 1.00 FBP1 (1.00) FBP1EGFRALDH1A1LMNAMAPT
SCHEMBL219464 1.00 FBP1 (1.00) FBP1EGFRALDH1A1LMNAMAPT
SCHEMBL6910815 0.89 FBP1 (0.78) FBP1EGFRALDH1A1LMNAMAPT
SCHEMBL6910818 0.89 FBP1 (0.78) FBP1EGFRALDH1A1LMNAMAPT
SCHEMBL5924031 0.78 FBP1 (0.67) FBP1EGFRTLR4TLR2ABL1
SCHEMBL2077031 0.78 FBP1 (1.00) FBP1EGFRALDH1A1LMNAMAPT
SCHEMBL421633 0.78 FBP1 (0.64) FBP1EGFRALDH1A1LMNAMAPT
SCHEMBL102630 0.78 FBP1 (1.00) FBP1EGFRALDH1A1LMNAMAPT
SCHEMBL366121 0.78 FBP1 (1.00) FBP1EGFRALDH1A1LMNAMAPT
SCHEMBL1681205 0.78 FBP1 (1.00) FBP1EGFRALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118844436-A Application of nitrostyrene compound in preventing and treating plant diseases and food-borne pathogenic bacteria 广西田园生化股份有限公司 2024-10-29 CN claimed
CN-114195646-B Preparation method of 1-chloro-4- (6-nitrocyclohex-3-enyl) -benzene 湖南化工研究院有限公司 2024-03-29 CN claimed
CN-112250581-B Preparation method of trans-4-chloro-beta-nitrostyrene 湖南海利常德农药化工有限公司 2023-03-17 CN claimed
CN-114195646-A Preparation method of 1-chloro-4- (6-nitrocyclohex-3-enyl) -benzene 湖南化工研究院有限公司 2022-03-18 CN claimed
CN-112250581-A Preparation method of trans-4-chloro-beta-nitrostyrene 湖南海利常德农药化工有限公司 2021-01-22 CN claimed
EP-2174927-B1 METHOD FOR PRODUCING BETA-NITROSTYRENE COMPOUND SUMITOMO CHEMICAL CO (JP) 2013-09-11 EP claimed
US-8067647-B2 Method for producing β-nitrostyrene compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-11-29 US claimed
US-20100130795-A1 METHOD FOR PRODUCING BETA-NITROSTYRENE COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED 2010-05-27 US claimed
EP-2174927-A1 METHOD FOR PRODUCING BETA-NITROSTYRENE COMPOUND Sumitomo Chemical Company, Limited (JP) 2010-04-14 EP claimed
WO-2025040089-A1 NOVEL HETEROCYCLIC COMPOUND FOR SELECTIVELY REGULATING CANNABINOID CB1 FUNCTION 德睿智药(苏州)新药研发有限公司 2025-02-27 WO disclosed
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-13 US disclosed
CN-118844436-A Application of nitrostyrene compound in preventing and treating plant diseases and food-borne pathogenic bacteria 广西田园生化股份有限公司 2024-10-29 CN disclosed
CN-118844436-A Application of nitrostyrene compound in preventing and treating plant diseases and food-borne pathogenic bacteria 广西田园生化股份有限公司 2024-10-29 CN disclosed
CN-118420514-A Method for synthesizing 3- (2-nitro-1-aryl) -1H-indole derivative by using cyclopentadienyl titanium/Bronsted acid in synergistic catalysis mode 宁夏师范学院 2024-08-02 CN disclosed
US-5013863-A Learning enhancement CIBA-GEIGY CORPORATION (US) 1991-05-07 US disclosed
US-5004826-A Chemical Intermediates For Muscle Relaxants, Muscle Stimulants, Analgesics, Anticonvulsants, Antidepressants, Nootropics, And Drugs For Reducing Drug Withdrawal Symptoms CIBA-GEIGY CORPORATION (US) 1991-04-02 US disclosed
EP-0181833-B1 SUBSTITUTED PROPANE-PHOSPHONOUS ACID COMPOUNDS CIBA-GEIGY AG (CH) 1990-05-02 EP disclosed
US-4908465-A Ethyl phenyl-3-nitropropyl(diethoxymethyl)phosphinate derivatives CIBA-GEIGY CORPORATION (US) 1990-03-13 US disclosed
US-4772738-A MUSCLE RELAXANTS, ANALGESICS, ANTICONVULSANTS, ANTIDEPRESSANT CIBA-GEIGY CORPORATION (US) 1988-09-20 US disclosed
US-4656298-A MUSCLE RELAXANTS, STIMULANTS, ANALGESICS, ANTICONVULSANTS, ANTIDEPRESSANTS CIBA-GEIGY CORPORATION (US) 1987-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130795-A1 METHOD FOR PRODUCING BETA-NITROSTYRENE COMPOUND NAT1, NOS1, NOS2 FBP1 2111/4885EGFR 4069/4885ALDH1A1 22/4885
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R FBP1 1903/4885EGFR 866/4885ALDH1A1 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.